Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK

Author： Jansen Jeroen P.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.12, 2009-12, pp. : 1045-1056

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ertapenem less costly than piperacillin/tazobactam in foot infections

By  

Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Piperacillin/Tazobactam: An Updated Review of its Use in the Treatment of Bacterial Infections

By Perry C.M.   Markham A.  

Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. : 805-843

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Apligraf ® Treatment of Diabetic Foot Ulcers

By Redekop W.K.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1171-1183

Adis International

Access to resources Recommend Favorite

Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection

By Dietrich E.S.   Schubert B.   Ebner W.   Daschner F.  

PharmacoEconomics, Vol. 19, Iss. 1, 2001-01 ,pp. : 79-94

Adis International

Access to resources Recommend Favorite

Piperacillin/Tazobactam: A Pharmacoeconomic Review of its Use in Moderate to Severe Bacterial Infections

By Young M.   Plosker G.L.  

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1135-1175

Adis International

Access to resources Recommend Favorite